Luzu (luliconazole) / Bausch Health 
Welcome,         Profile    Billing    Logout  
 7 Diseases   1 Trial   1 Trial   200 News 


1234»
  • ||||||||||  Luzu (luliconazole) / Bausch Health
    Preclinical, Journal:  Polymeric micelle gel with luliconazole: in vivo efficacy against cutaneous candidiasis in Wistar rats. (Pubmed Central) -  Sep 24, 2024   
    Finally, in vivo fungal scaling and histopathological studies indicated a reduction in fungal infection in Wistar rat skin after treatment. The obtained results suggested that LUL-PM can serve as a promising formulation to enhance luliconazole antifungal activity and increase patient compliance.
  • ||||||||||  Jublia (efinaconazole) / Bausch Health, Luzu (luliconazole) / Bausch Health, Nailin (fosravuconazole) / DNDi, Eisai
    Journal, Claims database:  Impact of new antifungal medications on onychomycosis prescriptions and costs in Japan: A nationwide claims database study. (Pubmed Central) -  Sep 2, 2024   
    The substantial increase in medical costs also highlights the economic burden of onychomycosis and the need for cost-effective treatment strategies. This study provides valuable insights into the real-world prescription trends and medical costs of onychomycosis treatment in Japan, suggesting an opportunity to assess potential gaps between guideline recommendations and clinical practice.
  • ||||||||||  epetraborole (AN3365) / AN2 Therap, Luzu (luliconazole) / Bausch Health, Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva
    Preclinical, Journal:  Evaluation of MMV Pandemic Response Box compounds to identify potent compounds against clinically relevant bacterial and fungal clinical isolates in vitro. (Pubmed Central) -  Jul 23, 2024   
    MMV1580854, MMV1579788, eravacycline and epetraborole inhibited both the bacterial test isolates...Five compounds from MMV Pandemic Box were found to be inhibiting colistin and ceftazidime resistant A. baumannii clinical isolate, also against colistin and ?-lactam resistant P. aeruginosa clinical isolate...MMV1782110, Eberconazole, amorolfine and luliconazole exhibited potent anti-fungal activity. Further investigations are warranted to identify the targets and mechanism.
  • ||||||||||  Jublia (efinaconazole) / Kaken Pharma, Bausch Health, Luzu (luliconazole) / Bausch Health, Nailin (fosravuconazole) / DNDi, Eisai, Sato Pharma
    Review, Journal:  Dermatophytomas in Onychomycosis: A Scoping Review of Prevalence, Diagnosis, and Treatment. (Pubmed Central) -  May 16, 2024   
    More clinical research and physician education are needed. Although dermatophytomas have historically been considered difficult to treat, the efficacy data gathered in this scoping review have demonstrated that newer topical treatments are effective, as are oral antifungals in combination with chemical or surgical methods.
  • ||||||||||  Jublia (efinaconazole) / Kaken Pharma, Bausch Health, Luzu (luliconazole) / Bausch Health
    Journal:  Development of treatment strategies by comparing the minimum inhibitory concentrations and minimum fungicidal concentrations of azole drugs in dermatophytes. (Pubmed Central) -  May 7, 2024   
    To assess the MICs of ITCZ, ravuconazole (RVCZ), efinaconazole (EFCZ), and luliconazole (LUCZ) in the isolates, broth microdilution assays were performed based on the Clinical and Laboratory Standards Institute M38-A2 guidelines with modifications...The MFCs in the dermatophytes were 1 to >32?mg/L for ITCZ, 0.06 to >32?mg/L for RVCZ, <0.03 to 4?mg/L for EFCZ, and <0.03 to 2?mg/L for LUCZ. If the drug susceptibility test shows that the fungi are resistant to the drug, the treatment can be changed to a susceptible drug in advance, or if the fungi are low-susceptible, the treatment can be done with the recognition that it may require a longer treatment period than usual.
  • ||||||||||  Luzu (luliconazole) / Bausch Health
    Journal:  Sulconazole induces pyroptosis promoted by interferon-? in monocyte/macrophage lineage cells. (Pubmed Central) -  Feb 28, 2024   
    Overall, the developed dual-drug-loaded electrospun nanofiber mats have good compatibility, surface properties, and excellent wound healing potential, which can provide an extra edge in the management of complex diabetic wounds. All six imidazole derivatives examined, namely ketoconazole, sulconazole, isoconazole, luliconazole, clotrimazole, and bifonazole, reduced the expression levels of inflammatory cytokines, such as interleukin (IL)-6 and tumor necrosis factor-?, after induction by lipopolysaccharide (LPS) in RAW264.7
  • ||||||||||  itraconazole / Generic mfg.
    Preclinical, Journal:  In vitro Azole Susceptibility Testing of Japanese Isolates of Itraconazole-Resistant Dermatophytes. (Pubmed Central) -  Nov 30, 2023   
    In all isolates, the minimum inhibitory concentrations (MICs) were > 32 mg/l for ITCZ, < 0.03 to 0.5 mg/l for ravuconazole (RVCZ), and < 0.03 mg/l for efinaconazole (EFCZ), luliconazole (LUCZ), and terbinafine (TRBF). Thus, in tinea unguium cases with ITCZ-resistant strains, treatment should be switched to TRBF or other azoles with a stronger antifungal efficacy, such as EFCZ, LUCZ, or RVCZ, and treatment must continue until the infectious organisms are completely eliminated.
  • ||||||||||  Luzu (luliconazole) / Bausch Health
    Clinico epidemiological and mycological study of Dermatophytosis with sensitivity testing () -  Jul 3, 2023 - Abstract #WCD2023WCD_7411;    
    KEY MESSAGE: Ointments containing Boric Acid (1%), Dithranol (0.1%), and Salicylic Acid (2%) (BADSA) should not be used in patients with SFI Dermatophytosis is commonly encountered in young and middle aged individuals with higher incidence among males.In our study Tinea corporis was the commonest presentation with most common agent isolated being Trichophyton rubrum.Among the 5 antifungal agents tested, Luliconazole has the lowest MIC range whereas Fluconazole has the highest range.This implies that Luliconazole is more potent than other agents
  • ||||||||||  Luzu (luliconazole) / Bausch Health
    Carbon Dioxide Laser Plus Topical 5% Luliconazole: A Better Combination Therapeutic Modality for Onychomycosis () -  Jul 3, 2023 - Abstract #WCD2023WCD_4125;    
    Dermatophytosis is commonly encountered in young and middle aged individuals with higher incidence among males.In our study Tinea corporis was the commonest presentation with most common agent isolated being Trichophyton rubrum.Among the 5 antifungal agents tested, Luliconazole has the lowest MIC range whereas Fluconazole has the highest range.This implies that Luliconazole is more potent than other agents Fractional CO2 laser combined with topical luliconazole 5% lotion is a safe and effective treatment for onychomycosis especially in those who have contraindications to oral antifungals
  • ||||||||||  Luzu (luliconazole) / Bausch Health
    Preclinical, Journal:  In Vitro and In Vivo Effect of the Imidazole Luliconazole against Lomentospora prolificans and Scedosporium spp. (Pubmed Central) -  Jun 19, 2023   
    These data reveal the previously unknown inhibitory effect of LLCZ against L. prolificans and its antibiofilm effect in Scedosporium spp. It represents an extension of the literature regarding azole-resistant fungi and could potentially lead to the development of future treatment strategies against these opportunistic fungal pathogens.
  • ||||||||||  Luzu (luliconazole) / Bausch Health
    Journal, Real-world evidence, Real-world:  Management of Dermatophytosis: Real-World Indian Perspective. (Pubmed Central) -  Jun 2, 2023   
    Additionally, 62% advise liver function tests (LFTs) at the initiation of therapy, whereas 72% advise monitoring adverse effects due to systemic antifungal drugs during treatment. Combination therapy stood out as the need of the hour in the current menace of dermatophytosis with timely monitoring of laboratory tests for adverse events due to the use of systemic antifungals for a longer duration.
  • ||||||||||  Luzu (luliconazole) / Bausch Health
    Retrospective data, Review, Journal:  Antifungal Resistance of Clinical Candida albicans Isolates in Iran: A Systematic Review and Meta-Analysis. (Pubmed Central) -  Apr 24, 2023   
    The lowest resistance levels among azoles were observed in luliconazole with a frequency of 0% and voriconazole of 3.94%. Due to the emergence of multi-drug resistant C. albicans, rational drug prescription based on the anti-fungal stewardship strategy and therapeutic drug monitoring is warranted.
  • ||||||||||  Luzu (luliconazole) / Bausch Health
    Journal:  Novel Luliconazole Spanlastic Nanocarriers: Development and Characterisation. (Pubmed Central) -  Mar 27, 2023   
    Due to the emergence of multi-drug resistant C. albicans, rational drug prescription based on the anti-fungal stewardship strategy and therapeutic drug monitoring is warranted. Collectively, the results revealed that spanlastics could be a potential nanocarrier for wellcontrolled delivery and for targeting deeper skin layers, thus providing new opportunities for dermal treatment.
  • ||||||||||  Luzu (luliconazole) / Bausch Health, Noxafil (posaconazole) / Merck (MSD), Cresemba (isavuconazonium sulfate) / Astellas, Basilea, Pfizer, Laboratoire Riva, Asahi Kasei
    Clinical, Journal:  Epidemiology and Antifungal Susceptibility of Candida Species Isolated from 10 Tertiary Care Hospitals in Iran. (Pubmed Central) -  Nov 30, 2022   
    However, amphotericin B and isavuconazole are also active against the most common Candida species isolated from patients. Pan azole-resistant Candida species were not observed in the present study.
  • ||||||||||  Luzu (luliconazole) / Bausch Health
    Review, Journal:  A Review of Characteristics, Properties, Application of Nanocarriers and Analytical Methods of Luliconazole. (Pubmed Central) -  Nov 10, 2022   
    The luliconazole has been qualitatively and quantitatively analyzed in different matrices, such as raw material and pharmaceutical formulations, however, in this review, only one study was found with the luliconazole quantification biological matrix, demonstrating the lack of studies related to the quantification of the drug in biological matrices. The drug quantification in different matrices by analytical methods is of great importance since they assist in the control of the quality, efficacy, and safety of the medicine.
  • ||||||||||  Jublia (efinaconazole) / Kaken, Bausch Health, Luzu (luliconazole) / Bausch Health, Kerydin (tavaborole) / Pfizer
    Review, Journal:  Novel and Investigational Treatments for Onychomycosis. (Pubmed Central) -  Oct 28, 2022   
    Efinaconazole, Tavaborole, and Luliconazole have been added to physicians' weaponry during the last decade, though launched on the market of a limited number of countries. The pipeline is either developing new products (e.g., ME-1111 and NP213) with an appealing combination of pharmacokinetic, efficacy, and safety properties or reformulating old, well-known drugs (Terbinafine and Amphotericin B) by using new excipients as penetration enhancers.